<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: The purpose of the present study was to conduct a systematic review and meta-analysis of the published literature to assess the diagnostic performance of FDG-PET or PET/CT in the detection of <z:e sem="disease" ids="C0854750" disease_type="Neoplastic Process" abbrv="">recurrent colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) rising in patients with elevated CEA </plain></SENT>
<SENT sid="1" pm="."><plain>MATERIALS AND METHODS: The authors conducted a systematic MEDLINE search of published articles </plain></SENT>
<SENT sid="2" pm="."><plain>Two reviewers independently assessed the methodological quality of each study </plain></SENT>
<SENT sid="3" pm="."><plain>We estimated pooled sensitivity and specificity and positive and negative likelihood ratios, and summary receiver-operating characteristic curves in the detection of recurrent <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> in patients with elevated CEA </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Eleven studies with a total of 510 patients met the inclusion criteria </plain></SENT>
<SENT sid="5" pm="."><plain>One hundred and six patients (106/510 = 20.8 %) had true-negative FDG-PET (PET/CT) results in detection of recurrent <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> when rising CEA </plain></SENT>
<SENT sid="6" pm="."><plain>The pooled estimates of sensitivity and specificity and positive and negative likelihood ratios of FDG-PET in the detection of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> recurrence in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients with elevated CEA were 90.3 % (95 % CI, 85.5-94.0 %), 80.0 % (95 % CI, 67.0-89.6 %), 2.88 (95 % CI, 1.37-6.07), and 0.12 (95 % CI, 0.07-0.20), respectively </plain></SENT>
<SENT sid="7" pm="."><plain>The pooled estimates of sensitivity and specificity and positive and negative likelihood ratios of FDG-PET/CT in the detection of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> recurrence in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients with elevated CEA were 94.1 % (95��% CI, 89.4-97.1 %), 77.2 % (95 % CI, 66.4-85.9 %), 4.70 (95 % CI, 0.82-12.13), and 0.06 (95 % CI, 0.03-0.13), respectively </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Whole-body FDG-PET and PET/CT are valuable imaging tools for the assessment of patients with suspected <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> recurrence based on the increase of CEA </plain></SENT>
</text></document>